Zambon Announces European Commission Approval of Hopledo for Parkinson’s Disease Motor Fluctuations
Milan, Italy – August 28, 2026 Zambon announced that the European Commission has granted marketing authorization for Hopledo® (modified-release...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Milan, Italy – August 28, 2026 Zambon announced that the European Commission has granted marketing authorization for Hopledo® (modified-release...
Ramat-Gan, Israel, July 28, 2026 Galmed Pharmaceuticals Ltd. has announced a significant advancement in the development of Aramchol orally...
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
